OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients

被引:26
|
作者
Wong, Ho-Tin [1 ]
Khalil, Modar [1 ]
Ahmed, Fayyaz [1 ,2 ,3 ,4 ]
机构
[1] Hull Univ Teaching Hosp, Dept Neurosci, Kingston Upon Hull, N Humberside, England
[2] Hull York Med Sch, Kingston Upon Hull, N Humberside, England
[3] Spire Hosp Hull, Kingston Upon Hull, N Humberside, England
[4] Spire Hosp East Riding, Kingston Upon Hull, N Humberside, England
来源
JOURNAL OF HEADACHE AND PAIN | 2020年 / 21卷 / 01期
关键词
Botox; OnabotulinumtoxinA; Pregnancy; Chronic migraine; Headache; BOTULISM;
D O I
10.1186/s10194-020-01196-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To report the pregnancy outcomes on patients with chronic migraine exposed to onabotulinumtoxinA from Hull Headache Clinic. Background Migraines are common in women of reproductive age and those with chronic migraine have a major impact on their activities of daily living and health-related quality of life. Apart from low dose amitriptyline and beta-blockers all other prophylactic agents have proven teratogenic effects. OnabotulinumtoxinA is approved as preventive treatment for adult patients with chronic migraine, although its impact on pregnancy is unknown. Methods We prospectively collected data for efficacy and safety on all patients treated with onabotulinumtoxinA at the Hull Headache Clinic. The toxin is administered as per PREEMPT paradigm. Female patients of reproductive age group receiving onabotulinumtoxinA are given advice on contraception and the unknown impact of the toxin on pregnancy. They are asked to report pregnancy when they are appraised on the risk/benefit of treatment continuation. All patients are consented for access to their medical records and pregnancy outcome and those who wished to continue are asked to sign a disclaimer. Pregnancy outcome data was collected on all patients for the mode of delivery, birth weight and congenital malformation and any other unexpected outcomes. Results Over 9 years period 45 patients reported pregnancy while receiving onabotulinumtoxinA. All patients had received onabotulinumtoxinA within 3 months prior to the date of conception. 32 patients wished to continue treatment during pregnancy while the remaining 13 stopped treatment. Apart from 1 miscarriage in the treatment group, all patients had full term healthy babies of normal birth weight and no congenital malformations. Conclusion We report our experience of 45 patients exposed to onabotulinumtoxinA during pregnancy. Although the numbers are small, there was no impact of the toxin found on the pregnancy outcomes.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Alsaadi, Taoufik
    Noori, Suzan
    Varakian, Razmig
    Youssef, Saly
    Almadani, AbuBaker
    [J]. BMC NEUROLOGY, 2022, 22 (01)
  • [22] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Taoufik Alsaadi
    Suzan Noori
    Razmig Varakian
    Saly Youssef
    AbuBaker Almadani
    [J]. BMC Neurology, 22
  • [23] Safety of Using OnabotulinumtoxinA for the Treatment of Chronic Migraine in Pregnancy
    Summers, J. E.
    Bedrin, K. O.
    Ailani, J.
    Dougherty, C. O.
    [J]. HEADACHE, 2020, 60 : 24 - 25
  • [24] Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Concurrent Cervical Dystonia and Chronic Migraine
    Rhyne, C.
    Martinez, K.
    Stoilova, J.
    Patel, A.
    Ifantides, K. Becker
    Singh, R.
    Yushmanova, I.
    Sadeghi, M.
    Battucci, S.
    Forde, G.
    [J]. MOVEMENT DISORDERS, 2023, 38 : S350 - S351
  • [25] OnabotulinumtoxinA (Botox) for Chronic Migraine during pregnancy; experience from Hull (UK) Headache clinic over 11 years
    Khan, Rafiullah
    Khalil, Modar
    Buture, Alina
    Wong, Ho-Tin
    Ahmed, Fayyaz
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 231 - 231
  • [26] LONG-TERM EXPERIENCE OF ONABOTULINUMTOXINA IN A LARGE SERIES OF CHRONIC MIGRAINE PATIENTS
    Lambru, G.
    Trimboli, M.
    Andreou, A. P.
    Murphy, M.
    Al-Kaisy, A.
    [J]. CEPHALALGIA, 2016, 36 : 47 - 47
  • [27] OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
    Isabel Pedraza, Maria
    de la Cruz, Carolina
    Ruiz, Marina
    Lopez-Mesonero, Luis
    Martinez, Elena
    de Lera, Mercedes
    Luis Guerrero, Angel
    [J]. SPRINGERPLUS, 2015, 4
  • [28] Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience
    Baldacci, Filippo
    Cafalli, Martina
    Lucchesi, Cinzia
    Mazzucchi, Sonia
    Dini, Elisa
    Bonuccelli, Ubaldo
    Gori, Sara
    [J]. JOURNAL OF HEADACHE AND PAIN, 2015, 16
  • [29] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine
    Mechtler, L. L.
    Saikali, N. P.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    [J]. HEADACHE, 2021, 61 : 176 - 177
  • [30] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 48 - 49